EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients
Kathleen M. Hill Gallant, Elizabeth R. Stremke, Laurie L. Trevino, Ranjani N. Moorthi, Simit Doshi, Meryl E. Wastney, Nozomi Hisada, Jotaro Sato, Yoshitaka Ogita, Naohisa Fujii, Yuya Matsuda, Takei Kake, Sharon M. Moe
Topics & Concepts
CrossoverCrossover studyHemodialysisBroad spectrumRandomized controlled trialMedicinePhase (matter)Intensive care medicinePhosphateInternal medicineChemistryComputer scienceAlternative medicinePathologyCombinatorial chemistryArtificial intelligenceOrganic chemistryPlaceboParathyroid Disorders and TreatmentsDialysis and Renal Disease ManagementGenetic and Kidney Cyst Diseases